{"artifact":{"id":"open_question-debate-pharmacology-1b0c7d40","artifact_type":"open_question","entity_ids":"[\"pharmacology\"]","title":"Can transferrin receptor-targeting nanocarriers loaded with SPM analogs achieve therapeutic concentrations at neuroinflammatory foci in large animal models without disrupting normal iron homeostasis o","quality_score":0.7,"created_by":"open_question_miner_debates","provenance_chain":"[]","content_hash":"71f375c090b362510bb71751651a93942988b548ee8b35e6bb2817c3fa5ccf74","metadata":{"status":"open","_origin":{"url":null,"type":"internal","tracked_at":"2026-04-28T06:05:59.219116"},"field_tag":"pharmacology","source_id":"sess_SDA-2026-04-01-gap-014","source_kind":"debate_session","question_hash":"1b0c7d4081106d3e","question_text":"Can transferrin receptor-targeting nanocarriers loaded with SPM analogs achieve therapeutic concentrations at neuroinflammatory foci in large animal models without disrupting normal iron homeostasis or causing off-target effects in peripheral tissues?","importance_elo":1500,"_schema_version":1,"evidence_summary":"Mined from debate session sess_SDA-2026-04-01-gap-014 (supporting_persona=synthesizer)","supporting_persona":"synthesizer","tractability_score":0.55,"verbatim_quote_offset":-1,"potential_impact_score":0.85,"is_answerable_in_principle":true},"created_at":"2026-04-27T23:05:59.219197-07:00","updated_at":"2026-04-27T23:05:59.219197-07:00","version_number":4,"parent_version_id":null,"version_tag":null,"changelog":null,"is_latest":1,"lifecycle_state":"active","superseded_by":null,"deprecated_at":null,"deprecated_reason":null,"dependencies":null,"market_price":0.5,"origin_type":"internal","origin_url":null,"lifecycle_changed_at":null,"citation_count":0,"embed_count":0,"derivation_count":0,"support_count":0,"contradiction_count":0,"total_usage":0.0,"usage_score":0.5,"usage_computed_at":null,"quality_status":null,"contributors":[],"answers_question_ids":null,"deprecated_reason_detail":null,"deprecated_reason_code":null,"commit_sha":null,"commit_submodule":null,"last_mutated_at":"2026-05-16T14:51:34.657673-07:00","disputed_at":null,"gap_id":null,"mission_id":null,"intrinsic_priority":null,"effective_priority":null,"artifact_id":"45c0dd26-cbd2-4b46-89b6-131d86b89f4c","artifact_dir":null,"primary_filename":null,"accessory_filenames":null,"folder_layout_version":1,"migrated_to_folder_at":null,"hypothesis_id":null,"authorship":{"kind":"human","contributors":[{"role":"author","actor_ref":"open_question_miner_debates"}]},"epistemic_tier":"T3_provisional","created_by_agent_id":null},"outgoing_links":[],"incoming_links":[],"current_artifact_id":"open_question-debate-pharmacology-1b0c7d40","is_canonical":true,"supersede_chain":["open_question-debate-pharmacology-1b0c7d40"]}